Dr. Nan Chen
Medical Oncology (Medical Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York Medical College (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 168
Licensed in Illinois since 2021, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: New York Medical College
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036156991 (first issued 2021; active) · IN license 01091761A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Franciscan Health Crown Point Crown Point, IN
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 168
- Services billed
- 685
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 162 | 78 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 121 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 35 | 31 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 28 |
| Hospital discharge day management, 30 minutes or less | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Chicago, IL | 182 |
| Anastrozole Other prescribers in Chicago, IL | 95 |
| Exemestane | 76 |
| Tamoxifen Citrate Other prescribers in Chicago, IL | 61 |
| Kisqali (ribociclib succinate) | 30 |
| Ibrance (palbociclib) | 25 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 24 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 21 |
| Gabapentin Other prescribers in Chicago, IL | 19 |
| Tukysa (tucatinib) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 24 payments worth $13,845 in total to this clinician.
| Genentech USA, Inc. | $4,686 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $3,309 |
| Tersera Therapeutics LLC | $3,280 |
| Daiichi Sankyo Inc. | $1,566 |
| Gilead Sciences, Inc. | $638 |
| Novartis Pharmaceuticals Corporation | $277 |
| Stemline Therapeutics Inc. | $88.84 |
| Consulting Fee | $11,393 |
|---|---|
| Food and Beverage | $920 |
| Speaking at a medical education program | $843 |
| Travel and Lodging | $490 |
| Long term medical supply or device loan | $199 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tersera Therapeutics LLC Sep 26, 2025 | Consulting Fee Zoladex · Oncology | $3,000 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Herceptin; Perjeta; Phesgo · BioOncology | $2,731 |
| AstraZeneca Pharmaceuticals LP Jun 16, 2025 | Consulting Fee | $1,675 |
| Genentech USA, Inc. Nov 6, 2025 | Consulting Fee | $1,230 |
| Daiichi Sankyo Inc. Apr 25, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,173 |
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Speaking at a medical education program | $843 |
| AstraZeneca Pharmaceuticals LP Apr 8, 2025 | Consulting Fee | $670 |
| Gilead Sciences, Inc. May 8, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4146994;VEM US;12663617 | $580 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Herceptin; Perjeta; Phesgo · BioOncology · travel to New York City, NY · in-kind | $375 |
| Daiichi Sankyo Inc. Jul 15, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $335 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Genentech USA, Inc. Nov 6, 2025 | Consulting Fee | $1,230 |
| Tersera Therapeutics LLC Sep 26, 2025 | Consulting Fee Zoladex · Oncology | $3,000 |
| Daiichi Sankyo Inc. Jul 15, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $335 |
| Genentech USA, Inc. Jul 10, 2025 | Consulting Fee Herceptin; Perjeta; Phesgo · BioOncology | $2,731 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Herceptin; Perjeta; Phesgo · BioOncology · travel to New York City, NY · in-kind | $375 |
| Genentech USA, Inc. Jul 10, 2025 | Travel and Lodging Herceptin; Perjeta; Phesgo · BioOncology · travel to New York City, NY | $106 |
| AstraZeneca Pharmaceuticals LP Jun 16, 2025 | Consulting Fee | $1,675 |
| Gilead Sciences, Inc. May 8, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4146994;VEM US;12663617 | $580 |
| Daiichi Sankyo Inc. Apr 25, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $1,173 |
| AstraZeneca Pharmaceuticals LP Apr 8, 2025 | Consulting Fee | $670 |
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Speaking at a medical education program | $843 |
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Travel and Lodging travel to Chicago, IL | $8.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $259,608 in research payments for these studies, mostly to the institutions running them.
- An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
Merck Sharp & Dohme LLC - ALI-1201
Puma Biotechnology, Inc. - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus letrozole compared to CDK46 inhibitor plus letrozole in participants over 18 years of age with hormone receptor hrpositive HER2NEGATI…
Pfizer Inc. - A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT04975308
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.